Advertisement
Advertisement
U.S. Markets open in 8 hrs 53 mins
Advertisement
Advertisement
Advertisement
Advertisement

Pharming Group N.V. (PHAR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.70-0.96 (-8.23%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.66
Open10.74
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range9.87 - 10.74
52 Week Range6.10 - 12.98
Volume17,543
Avg. Volume4,081
Market Cap685.183M
Beta (5Y Monthly)1.48
PE Ratio (TTM)35.67
EPS (TTM)0.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Pharming's Leniolisib Goes Under Priority FDA Review For Rare Immune System Disorder

    The FDA has accepted Pharming Group NV's (NASDAQ: PHAR) marketing application seeking approval for leniolisib for rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification. Submitted by Pharming on July 29, 2022, the application was supported by positive data from a Phase 2/3 study of leniolisib, which me

  • CNW Group

    Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. The FDA has assigned a Prescription

  • PR Newswire

    CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference

    Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.

Advertisement
Advertisement